Sanofi Sues Watson, Glenmark Over Planned Multaq Generics

Law360, New York (February 27, 2014, 4:53 PM EST) -- Pharmaceutical company Sanofi SA slapped two drugmakers with patent infringement suits in Delaware federal court on Wednesday in an attempt to block the companies from manufacturing generic versions of its heart rhythm medication Multaq.

France-based Sanofi and its U.S. subsidiary, Sanofi-Aventis U.S. LLC, claim that Glenmarks Generics Inc. Ltd. and Actavis Inc. subsidiary Watson Laboratories Inc. have infringed on three patents associated with Multaq by filing applications with the U.S. Food and Drug Association to produce generic versions of the drug.

“Plaintiffs will be irreparably harmed by...
To view the full article, register now.